What Do Hedge Funds Have To Say About These 3 Purchases?

Page 1 of 2

Most hedge funds and other money managers tracked by Insider Monkey have not submitted their 13F filings for the September quarter just yet. These public filings will surely disclose attractive and attention-grabbing stock picks, but it might take a few more days until market participants will get the chance to take a look at them (the deadline is November 15 for the current filing period). In the meantime, several hedge funds have been revealing 13G, 13D, and Form 4 filings regarding some of their positions, which usually disclose up-to-date insights about their major stances on different companies. So let’s proceed with a discussion on three such moves made by elite hedge funds tracked by our team.

Kevin Kotler

We track hedge funds and prominent investors because our research has shown that historically their stock picks delivered superior risk-adjusted returns. This is especially true in the small-cap space. The 50 most popular large-cap stocks among hedge funds had a monthly alpha of about six basis points per month between 1999 and 2012; however the 15 most popular small-cap stocks delivered a monthly alpha of 80 basis points during the same period. This means investors would have generated 10 percentage points of alpha per year simply by imitating hedge funds’ top 15 small-cap ideas. We have been tracking the performance of these stocks since the end of August 2012 in real time and these stocks beat the market by 53 percentage points (102% return vs. S&P 500’s 48.7% gain) over the last 37 months (see the details here).

In a Schedule 13G filing with the U.S. Securities and Exchange Commission, Kevin Kotler’s Broadfin Capital disclosed owning 1.81 million shares of Aratana Therapeutics Inc. (NASDAQ:PETX), which represent 5.17% of the company’s outstanding common stock. This denotes a lift of exactly 678,000 shares from Broadfin’s position disclosed through its 13F filing for the second quarter. The shares of the pet therapeutics company plummeted in September, after it disclosed disappointing clinical trial results. Specifically, Aratana Therapeutics Inc. (NASDAQ:PETX)’s management acknowledged that two of its product candidates will not reach the desired and previously-anticipated lymphoma market opportunity for canines. Partially due to that, the stock is down by 55% year-to-date.

Follow Kevin Kotler's Broadfin Capital

The hedge fund sentiment towards the company did not change significantly during the second quarter, as the number of hedge funds invested in the stock increased to 13 from 12 quarter-over-quarter. These top money managers stockpiled approximately 15% of the company’s shares on June 30. At the same time, the value of their stakes in Aratana increased to $78.34 million from $52.78 million during the three-month period. Healthcare-focused Sio Capital, led by Michael Castor held a 404,738-share stake in Aratana Therapeutics Inc. (NASDAQ:PETX) at the end of the June quarter (read more details).

Follow Aratana Therapeutics Inc. (NASDAQ:PETX)

Let’s move on to the next page of the article, where we disclose the moves made by Carlson Capital and JANA Partners.

Page 1 of 2